|
Disease |
|
|
|
Detail |
| hsa-miR-155 |
|
Unspecified |
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. |
2005 |
|
|
|
|
|
|
| hsa-miR-143 |
|
Causal |
Downregulation of microRNAs-143 and -145 in B-cell malignancies. |
2007 |
|
|
|
|
|
|
| hsa-miR-145 |
|
Causal |
Downregulation of microRNAs-143 and -145 in B-cell malignancies. |
2007 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Causal |
MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. |
2006 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Unspecified |
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. |
2005 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Unspecified |
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. |
2008 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Unspecified |
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. |
2008 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Unspecified |
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Unspecified |
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-221 |
|
Unspecified |
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-3p |
|
Causal |
Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. |
2007 |
|
|
|
|
|
|
| hsa-miR-20a |
|
Unspecified |
A microRNA cluster as a target of genomic amplification in malignant lymphoma. |
2005 |
|
|
|
|
|
|
| hsa-miR-17-3p |
|
Unspecified |
A microRNA cluster as a target of genomic amplification in malignant lymphoma. |
2005 |
|
|
|
|
|
|
| hsa-miR-92-1 |
|
Unspecified |
A microRNA cluster as a target of genomic amplification in malignant lymphoma. |
2005 |
|
|
|
|
|
|
| hsa-miR-19a |
|
Unspecified |
A microRNA cluster as a target of genomic amplification in malignant lymphoma. |
2005 |
|
|
|
|
|
|
| hsa-miR-19b |
|
Unspecified |
A microRNA cluster as a target of genomic amplification in malignant lymphoma. |
2005 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA cluster as a target of genomic amplification in malignant lymphoma. |
2005 |
|
|
|
|
|
|
| hsa-miR-17-92 |
|
Causal |
A microRNA polycistron as a potential human oncogene. |
2005 |
|
|
|
|
|
|
| hsa-miR-16-1 |
|
Causal |
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. |
2008 |
|
|
|
|
|
|
| hsa-let-7e |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-210 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-95 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-99a |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-10a |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-155 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-139 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-320 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-328 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-149 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-150 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-151 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-106a |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-145 |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-17 |
|
Causal |
MicroRNA-17-92 downregulates expression of distinct targets in different B-cell lymphoma subtypes. |
2008 |
|
|
|
|
|
|
| hsa-miR-20a |
|
Causal |
MicroRNA-17-92 downregulates expression of distinct targets in different B-cell lymphoma subtypes. |
2008 |
|
|
|
|
|
|
| hsa-miR-127 |
|
Unspecified |
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. |
2009 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. |
2009 |
|
|
|
|
|
|